That's essential, due to the fact that the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be efficient. To put it simply, we have to understand how these proteins fold if we want a drug to work. Historically, this has actually been an experimental procedure (angel investor). Today, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to produce drugs that do what they're designed to do. This was a breakthrough practically no one discovered. But it's going to have extensive ramifications for treating disease. I anticipate that Alpha, Fold will be 98% precise by the end of 2021.
And, naturally, there will be lots of investment opportunities in this area, too. Moving topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (jeff brown). That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I would not be shocked if it drew back maybe significantly before going higher - jeff brown stock picks 2021. I've been covering bitcoin for a long time now. Among the first research reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary suggestion, I entitled my report "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time. We were primarily educating readers. But that's not the big question anymore. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. Mass, Mutual is a trusted 170-year-old institution. So think about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. self-driving cars. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I anticipate 2021 will be another record year in IPOs. There are many great personal business on the verge of hitting the public markets And I've been working on a brand-new method for you to invest even before these business go public.
This chance has actually been developing over the last few years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the information. Go right here to reserve your spot free of charge.
Emma Walsh here, managing editor of the Diary. Regular Diary readers understand that tech isn't our normal beat (longtime readers). And when it pertains to tech investing, we leave it to the specialists. The good news is, we have numerous such specialists in our Rolodex. Our coworker Jeff Brown will be familiar to our long time readers. He is one of the most accomplished tech investing specialists we know (jeff brown biotech stock). In reality, he had a number of triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take an appearance at the huge image and predict what's simply around the corner.
That consists of things like 5G networks, biotech, synthetic intelligence, and far more. These trends are experiencing rapid growth and creating incredible chances for investors. I wish to ensure all our readers are prepared for what's next. And with that in mind, let me draw the picture of what I see can be found in the next 12 months Our brand-new 5G (fifth-generation) wireless networks are a subject I've been covering for years now. bleeding edge. However in spite of what many readers may think, this is a pattern that's just starting. Despite the fact that the COVID-19 pandemic interrupted supply chains in 2015, an outstanding 250 million 5G-enabled devices were still sold.
And all of this ultimately resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (jeff brown biotech stocks). Losing 2 months of production and sales actually impacts the number of 5G devices are sold in the calendar year. When you think about all of that, selling 250 million systems is exceptional. More significantly, the delays caused by the pandemic created a lots of pent-up need. And that need is now going to be pushed into 2021. In reality, I anticipate that more than 500 million 5G gadgets will be delivered in 2021 - jeff brown 1 biotech. Which's not my only 5G prediction When I have actually talked about 5G in the past, I have actually described its 3 different stages.
In Stage 2, 5G gadgets go on sale. 5G phones and other products begin to reach consumers. And in Phase Three, 5G services start to be used (toxic tech 5 tech darlings). That's when we start to see applications operating on 5G networks. Believe of things like massive multiplayer video games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Stage Three by this summertime. This starts something of a virtuous cycle: The majority of individuals do not really appreciate the technology. But they will care if there are amazing applications that can only be accessed with a 5G phone.
That causes more 5G apps being developed. In fact, 5G is going to open a suite of extraordinary applications: self-driving automobiles, the Web of Things, robotic surgical treatment, and more. All of these innovations require 5G. The investment chances moving forward will be massive. Stepping away from 5G, the next crucial innovation I foresee in 2021 is CRISPR hereditary editing. CRISPR represents "clustered frequently interspaced short palindromic repeat." It's a mouthful. However it is among the most exciting developments in biotechnology. At a high level, CRISPR is a technology that can edit our hereditary makeup as if it were software application.
The program can crash or not work properly. CRISPR uses a similar idea however with our hereditary code. "Typos" in our genome can result in disease. CRISPR can correct these "typos." For several years, CRISPR was mostly a specific niche technology that wasn't well understood. And throughout that time, there were actually just 3 companies operating in this space. But things are altering. CRISPR is no longer just theoretical. We're seeing real outcomes. We're dealing with illness and seeing that this technology simply works. And as an outcome, a "second crop" of early-stage CRISPR business is going public and delivering extraordinary returns. This whole market is efficiently a greenfield opportunity.
There's room for lots of business to exist in this space. toxic tech 5 tech darlings. And there will be more. That's my prediction for CRISPR in 2021. I forecast that two or three more hereditary editing business will hold their IPOs. Sticking to biotechnology, we are seeing remarkable things occurring at the convergence of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its latest Alpha, Fold software can properly anticipate the folding of a protein based solely on its amino acid sequence with 92. 4% accuracy. That's essential since the way a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and be efficient.
Historically, this has actually been an experimental process. Today, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to develop drugs that do what they're developed to do. And here's my next prediction. I predict that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however several drug therapies produced using this technology. This was one of those breakthroughs that almost nobody saw. However it's going to have extensive implications for treating illness. And, obviously, there will be a lot of investment chances in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be surprised if it pulled back perhaps substantially before going greater. I have actually been covering bitcoin for a long time now. One of the very first research reports I ever published was on bitcoin - united arab emirates. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ roi for anybody who followed my suggestion. But at the time of that preliminary recommendation, I entitled my report, "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time.
But no one is asking that concern anymore. Now, we're seeing institutional money lastly taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. jeff brown top biotech 2020. Mass, Mutual is a 150-year-old organization. So think about that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus offer prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the information is up to date since February 2021, but we could not individually verify this claim. Given Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an accurate figure at this minute. Brown is best known for his sage-like ability to choose winning innovation stocks. He spent more than 25 years investigating technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience offers him an excellent point of view on the marketplace. He's constantly on the hunt for brand-new opportunities, and he shares a lot of his finest picks in the Future Report.
That's high praise, however it's not ridiculously reasoned. Brown has an exceptional credibility as a stock-picker, and he successfully predicted some of the greatest financial events of the previous 20 years. Although he does not appear to launch his picks to the public, the service's success is a direct sign of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal every time, however Jeff Brown's precise forecasts have earned him legions of devoted followers. That states a lot about his ability. The Near Future Report is published by Brownstone Research, a prominent financial research study publisher. Brownstone Research study offers a number of research study services with a wide variety of specializations - second wave.
The business is also associated with Bonner & Partners, another well-respected research publisher - united arab emirates. On its website, Brownstone states its mission is to supply retail financiers with professional-grade research study: "For too long, the best investment research has actually not been readily available to specific investors. It has been usually booked for investment banks, hedge funds, private equity, and high-net-worth clients. democratic republic. The mission of Brownstone Research study is to make that kind of proprietary research offered to any investors looking to acquire an edge in the markets. The goal is basic to deliver special and lucrative financial investment research discovered no place else." -Brownstone Research site excerpt from the Jeff Brown is the creator of Brownstone Research study, and he likewise serves as the company's Chief Investment Expert.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After years of consistent success at the helm of top-tier business like Tesla and Space, X, Elon Musk is a family name throughout the majority of America. If you know even a bit about the market, you understand that he has a reputation as a King Midas of sorts. jeff brown biotech picks. Whatever he touches relies on gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big task.
In truth, Brown believes S.A.V. first lady. might be "the biggest pattern of the 2020s, and he's not alone. Have a look at these quotes from other popular S.A.V. bulls: Elon's next big act will be marrying two innovative innovations: artificial intelligence and electric cars and trucks. Musk hopes the combination will help him establish the first fully-autonomous, self-driving cars and trucks ever. It's nothing brief of the automotive market's Holy Grail. As you know, electric cars and self-driving vehicle stocks have been big this year, but the Wall Street machine has been big on hype without much tangible outcome. In spite of an extreme boost in competition over the past couple of years, Brown still thinks Musk has the best opportunity of putting it all together.
tech could be the magic string that ties everything together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transportation. Basically, this technology would allow you to lease out your automobile as an autonomous, self-driving taxi when you're not using it. You just leave the car and press a button on an app that informs the vehicle to "join the fleet." Next thing you know, you're relaxing on your couch while your automobile shuttles ride-sharers around town. Best of all, you get to keep a substantial chunk of the revenues. It sounds ridiculous, but it could be closed than you think.